The New England journal of medicine, 2021-12, Vol.385 (26), p.2431-2440
2021
Volltextzugriff (PDF)
Details
- Autor(en) / Beteiligte
- Titel
- Trial of Spesolimab for Generalized Pustular Psoriasis
- Ist Teil von
- The New England journal of medicine, 2021-12, Vol.385 (26), p.2431-2440
- Ort / Verlag
- United States: Massachusetts Medical Society
- Erscheinungsjahr
- 2021
- Quelle
- MEDLINE
- Beschreibungen/Notizen
- In a randomized trial involving patients with the rare but disabling disorder generalized pustular psoriasis, the anti–interleukin-36 monoclonal antibody spesolimab greatly curtailed disease activity as compared with placebo over a period of 1 week. Systemic drug reactions and infections occurred with spesolimab.
- Sprache
- Englisch
- Identifikatoren
- ISSN: 0028-4793eISSN: 1533-4406DOI: 10.1056/NEJMoa2111563Titel-ID: cdi_proquest_miscellaneous_2613295132
- Format
- –
- Schlagworte
- Adult, Aged, Allergy, Antibodies, Monoclonal, Humanized - administration & dosage, Antibodies, Monoclonal, Humanized - adverse effects, Antibodies, Monoclonal, Humanized - therapeutic use, Autoimmune Disease, Autoimmune diseases, Clinical medicine, Clinical trials, Cytokines, Dermatology, Double-Blind Method, Drug dosages, Erythema, Female, Health aspects, Humans, Immunology, Injections, Intravenous, Interleukins, Intravenous administration, Male, Middle Aged, Monoclonal antibodies, Mutation, Pain, Patient safety, Patients, Placebos, Placebos - adverse effects, Placebos - therapeutic use, Psoriasis, Psoriasis - drug therapy, Receptors, Interleukin - antagonists & inhibitors, Severity of Illness Index, Skin, Skin diseases, Statistical analysis, Symptom Flare Up